OD1 Toxin

OD1 Toxin is a scorpion peptide that was originally isolated from the venom of the scorpion Odonthobuthus doriae.1  OD1 is a 65 residue peptide stabilized by 4 intramolecular disulfide bonds.2  OD1 potently inhibits fast inactivation of mammalian channels Nav1.7 (EC50 4.5 nM), Nav1.4 (EC50 10 ± 2 nM) and Nav1.6 (EC50 47 ± 10 nM).1  OD1 also blocks fast inactivation of the para/tipE insect channel (EC50 80 nM). OD1 weakly affects mammalian Nav1.3 and Nav1.5 (EC50 > 1 μM) and does not affect Nav1.2 and Nav1.8. OD1 induces spontaneous pain when injected in animal in association with or without veratridine and can be used to test the analgesic effects of Nav1.7 blockers in-vivo.3  We are pleased to offer our first α-type scorpion Nav channel toxin for your research needs.

Sequence: H-Gly-Val-Arg-Asp-Ala-Tyr-Ile-Ala-Asp-Asp-Lys-Asn-Cys-Val-Tyr-Thr-Cys-Ala-Ser-Asn-Gly-Tyr-Cys-Asn-Thr-Glu-Cys-Thr-Lys-Asn-Gly-Ala-Glu-Ser-Gly-Tyr-Cys-Gln-Trp-Ile-Gly-Arg-Tyr-Gly-Asn-Ala-Cys-Trp-Cys-Ile-Lys-Leu-Pro-Asp-Glu-Val-Pro-Ile-Arg-Ile-Pro-Gly-Lys-Cys-Arg-NH2 

Disulfide Bonds: C13-C64 ; C17-C37 ; C23-C47 ; C27-C49

  1. A. Jalali, et al., OD1, the first toxin isolated from the venom of the scorpion Odonthobuthus doriae active on voltage-gated Na+ channels. FEBS,579, 4181 (2005). PMID: 16038905
  2. T. Durek, et al., Chemical Engineering and Structural and Pharmacological Characterization of the α‑Scorpion Toxin OD1. Chem. Biol., 8, 1215 (2013). PIMD: 3527544
  3. Maertens, et al., Potent Modulation of the Voltage-Gated Sodium Channel Nav1.7 by OD1, a Toxin from the Scorpion Odonthobuthus doriae. Mol. Pharmacol., 70(1), 405 (2006). PMID: 16641312

Industry News , Biologically Active Peptides , Peptides International News

Dr. Michael W. Pennington

See all articles from Dr. Michael W. Pennington

Dr. Michael Pennington joined Peptides International in December 2010 as Chief Technology Officer. On January 1, 2013, Dr. Pennington's role became that of President and Chief Executive Officer. After doctoral research at University of Florida, he joined the pharmaceutical industry in the Department of Biotechnology at Schering-Plough. He joined Bachem Biosciences in King of Prussia, PA as a Principle Scientist in the Peptide Chemistry department. Dr. Pennington served as the Group Director for Bachem Biosciences before being appointed as President and C.O.O., a positioned he maintained from 2000 – 2010. He built and directed an internationally recognized peptide chemistry team focused on producing complex peptides and toxins. Dr. Pennington was a member of Bachem Forschungausschuss, the International Research and Development from 2000 – 2010. He has extensive collaborations with both industrial and academic scientists and maintains an extramurally funded research program on several peptide toxins. He is a founder of Airmid Inc., a biotech venture company dedicated to advancing two of his discoveries into clinical development for autoimmune diseases. Dr. Pennington has been awarded four patents and over 85 peer reviewed scientific articles, and serves as an editor of International Journal of Peptide Research and Therapeutics and Current Peptide and Protein Letters. He holds a Bachelor of Chemistry degree from the University of North Carolina at Chapel Hill and a Ph.D. from University of Florida at Gainesville.